Role of Pseudomonas aeruginosa type III effectors in disease

Current Opinion in Microbiology

Volumn 12, Issue 1, 2009, Pages 61-66

  Engel, Joanne ^a   Balachandran, Priya ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADP RIBOSE TRANSFERASES; BACTERIAL PROTEINS; BACTERIAL TOXINS; ENZYMES; GLUCOSYLTRANSFERASES; GTPASE-ACTIVATING PROTEINS; HOST-PATHOGEN INTERACTIONS; HUMANS; MEMBRANE TRANSPORT PROTEINS; PROTEIN TRANSPORT; PSEUDOMONAS AERUGINOSA; VIRULENCE FACTORS;

PSEUDOMONAS AERUGINOSA;

EID: 59849110833     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mib.2008.12.007     Document Type: Review

References (50)

1. Hauser A., Cobb E., Bodi M., Mariscal D., Valles J., Engel J., and Rello J. Impact of Pseudomonas aeruginosa type III secretion on clinical outcomes in patients with ventilator-associated pneumonia. Crit Care Med 30 (2002) 521-528
2. Lau G.W., Hassett D.J., and Britigan B.E. Modulation of lung epithelial functions by Pseudomonas aeruginosa. Trends Microbiol 13 (2005) 389-397
3. Ma Q., Zhai Y., Schneider J.C., Ramseier T.M., and Saier Jr. M.H. Protein secretion systems of Pseudomonas aeruginosa and P. fluorescens. Biochim Biophys Acta 1611 (2003) 223-233
4. Filloux A., Hachani A., and Bleves S. The bacterial type VI secretion machine: yet another player for protein transport across membranes. Microbiology 154 (2008) 1570-1583
5. Engel J.N. Molecular pathogenesis of acute Pseudomonas aeruginosa infections. In: Hauser A., and Rello J. (Eds). Severe Infections Caused by Pseudomonas aeruginosa (2003), Kluwer Academic/Plenum Press 201-230
6. Kulasekara B.R., Kulasekara H.D., Wolfgang M.C., Stevens L., Frank D.W., and Lory S. Acquisition and evolution of the exoU locus in Pseudomonas aeruginosa. J Bacteriol 188 (2006) 4037-4050
7. Feltman H., Schulert G., Khan S., Jain M., Peterson L., and Hauser A.R. Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. Microbiology 147 (2001) 2659-2669
8. Jain M., Ramirez D., Seshadri R., Cullina J.F., Powers C.A., Schulert G.S., Bar-Meir M., Sullivan C.L., McColley S.A., and Hauser A.R. Type III secretion phenotypes of Pseudomonas aeruginosa strains change during infection of individuals with cystic fibrosis. J Clin Microbiol 42 (2004) 5229-5237
9. Sitkiewicz I., Stockbauer K.E., and Musser J.M. Secreted bacterial phospholipase A2 enzymes: better living through phospholipolysis. Trends Microbiol 15 (2007) 63-69. An excellent review of bacterial phospholipases.
10. Sato H., Feix J.B., and Frank D.W. Identification of superoxide dismutase as a cofactor for the Pseudomonas type III toxin, ExoU. Biochemistry 45 (2006) 10368-10375
11. Stirling F.R., Cuzick A., Kelly S.M., Oxley D., and Evans T.J. Eukaryotic localization, activation and ubiquitinylation of a bacterial type III secreted toxin. Cell Microbiol 8 (2006) 1294-1309
12. Rabin S.D., Veesenmeyer J.L., Bieging K.T., and Hauser A.R. A C-terminal domain targets the Pseudomonas aeruginosa cytotoxin ExoU to the plasma membrane of host cells. Infect Immun 74 (2006) 2552-2561
13. McMorran B., Town L., Costelloe E., Palmer J., Engel J., Hume D., and Wainwright B. Effector ExoU from the type III secretion system is an important modulator of gene expression in lung epithelial cells in response to Pseudomonas aeruginosa infection. Infect Immun 71 (2003) 6035-6044
14. Cuzick A., Stirling F.R., Lindsay S.L., and Evans T.J. The type III pseudomonal exotoxin U activates the c-Jun NH2-terminal kinase pathway and increases human epithelial interleukin-8 production. Infect Immun 74 (2006) 4104-4113
15. Saliba A.M., Nascimento D.O., Silva M.C., Assis M.C., Gayer C.R., Raymond B., Coelho M.G., Marques E.A., Touqui L., Albano R.M., et al. Eicosanoid-mediated proinflammatory activity of Pseudomonas aeruginosa ExoU. Cell Microbiol 7 (2005) 1811-1822
16. Henderson F.C., Miakotina O.L., and Mallampalli R.K. Proapoptotic effects of P. aeruginosa involve inhibition of surfactant phosphatidylcholine synthesis. J Lipid Res 47 (2006) 2314-2324
17. El Solh A.A., Akinnusi M.E., Wiener-Kronish J.P., Lynch S.V., Pineda L.A., and Szarpa K. Persistent infection with Pseudomonas aeruginosa in ventilator-associated pneumonia. Am J Respir Crit Care Med 178 (2008) 513-519. This study demonstrates that type III secretion-producing strains of P. aeruginosa are less likely to be cleared from lungs of mechanically ventilated patients after 8 days of appropriate antibiotics and provides support for the current practice of treating these patients for a longer period of time.
18. Diaz M.H., Shaver C.M., King J.D., Musunuri S., Kazzaz J.A., and Hauser A.R. Pseudomonas aeruginosa induces localized immunosuppression during pneumonia. Infect Immun 76 (2008) 4414-4421. This study demonstrates that ExoU inhibits neutrophil function in the lungs of infected mice and provides insight into why ExoU-producing strains might be especially virulent. It also suggests that patients with P. aeruginosa pneumonia caused by ExoU-producing strains might be especially vulnerable to secondary infections with other pathogens.
19. Sutterwala F.S., Mijares L.A., Li L., Ogura Y., Kazmierczak B.I., and Flavell R.A. Immune recognition of Pseudomonas aeruginosa mediated by the IPAF/NLRC4 inflammasome. J Exp Med 204 (2007) 3235-3245. The authors demonstrate that ExoU can inhibit Ipaf driven caspase-1 production and processing of IL-1beta. In contrast to [44], the authors showed that flagellin was not an activator of the inflammasome-mediated cytokine response.
20. Cowell B.A., Evans D.J., and Fleiszig S.M. Actin cytoskeleton disruption by ExoY and its effects on Pseudomonas aeruginosa invasion. FEMS Microbiol Lett 250 (2005) 71-76
21. Arnoldo A., Curak J., Kittanakom S., Chevelev I., Lee V.T., Sahebol-Amri M., Koscik B., Ljuma L., Roy P.J., Bedalov A., et al. Identification of small molecule inhibitors of Pseudomonas aeruginosa exoenzyme S using a yeast phenotypic screen. PLoS Genet 4 (2008) e1000005. The authors used a cell-based yeast phenotypic assay, combined with a large-scale inhibitor screen, to identify small molecule inhibitors that can suppress the toxicity caused by heterologous expression of some P. aeruginosa ORFs. They identified exosin, which inhibits ExoS ADPRT activity. Exosin, and two of its analogs, protected mice against P. aeruginosa infection in vivo. The authors identified in yeast several homologs of known ExoS targets, as well as the yeast homolog of FAS, suggesting that the mechanism of toxin action is conserved from yeast to humans.
22. Barbieri J.T., and Sun J. Pseudomonas aeruginosa ExoS and ExoT. Rev Physiol Biochem Pharmacol 152 (2004) 79-92
23. Deng Q., and Barbieri J.T. Modulation of host cell endocytosis by the type III cytotoxin Pseudomonas ExoS. Traffic 9 (2008) 1948-1957. The authors demonstrate that the RhoGAP activity of ExoS inhibits bacterial internalization and phagocytosis, whereas the ExoS ADPRT activity inhibited vesicle trafficking by interfering with Rab 5 function.
24. Zhang Y., Deng Q., and Barbieri J.T. Intracellular localization of type III-delivered Pseudomonas ExoS with endosome vesicles. J Biol Chem 282 (2007) 13022-13032. This study, along with [25] demonstrates that the membrane localization domain of ExoS is required for localization of translocated ExoS to the plasma membrane followed appearance in perinuclear regions, where it was found associated with 14-3-3 proteins and Rab 5, Rab 6, and Rab 9. Membrane localization was required for ADP ribosylation of Ras and for GAP activity toward Rac. Together, these results suggest that membrane localization helps to specify target modification.
25. Deng Q., Zhang Y., and Barbieri J.T. Intracellular trafficking of Pseudomonas ExoS, a type III cytotoxin. Traffic 8 (2007) 1331-1345
26. Deng Q., and Barbieri J.T. Molecular mechanisms of the cytotoxicity of ADP-ribosylating toxins. Annu Rev Microbiol 62 (2008) 271-288. A comprehensive review of bacterial ADPRTs.
27. Ottmann C., Yasmin L., Weyand M., Veesenmeyer J.L., Diaz M.H., Palmer R.H., Francis M.S., Hauser A.R., Wittinghofer A., and Hallberg B. Phosphorylation-independent interaction between 14-3-3 and exoenzyme S: from structure to pathogenesis. EMBO J 26 (2007) 902-913. The authors determined the structure of ExoS bound to FAS and determine that this 14-3-3 family member binds to ExoS in a novel way that does not require a phosphoserine.
28. ••], demonstrates that in addition to the previously known ability of ExoT to inhibit cell migration, each domain of ExoT can independently inhibit cell division. The GAP activity of ExoT inhibits Rho, which is required at early stages of cytokinesis. The ADPRT activity, by inhibiting Crk function, prevents the final stage of cytokinesis, daughter cell separation. These studies provide the first evidence for the involvement of Crk and other focal adhesion proteins in cytokinesis.
29. Sun J., Maresso A.W., Kim J.J., and Barbieri J.T. How bacterial ADP-ribosylating toxins recognize substrates. Nat Struct Mol Biol 11 (2004) 868-876
30. Maresso A.W., Deng Q., Pereckas M.S., Wakim B.T., and Barbieri J.T. Pseudomonas aeruginosa ExoS ADP-ribosyltransferase inhibits ERM phosphorylation. Cell Microbiol 9 (2007) 97-105
31. DiNovo A.A., Schey K.L., Vachon W.S., McGuffie E.M., Olson J.C., and Vincent T.S. ADP-ribosylation of cyclophilin A by Pseudomonas aeruginosa exoenzyme S. Biochemistry 45 (2006) 4664-4673
32. Alaoui-El-Azher M., Jia J., Lian W., and Jin S. ExoS of Pseudomonas aeruginosa induces apoptosis through a Fas receptor/caspase 8-independent pathway in HeLa cells. Cell Microbiol 8 (2006) 326-338
33. Jia J., Alaoui-El-Azher M., Chow M., Chambers T.C., Baker H., and Jin S. c-Jun NH2-terminal kinase-mediated signaling is essential for Pseudomonas aeruginosa ExoS-induced apoptosis. Infect Immun 71 (2003) 3361-3370
34. Soong G., Parker D., Magargee M., and Prince A.S. The type III toxins of Pseudomonas aeruginosa disrupt epithelial barrier function. J Bacteriol 190 (2008) 2814-2821. The authors demonstrate that T3SS proteins of P. aeruginosa disrupt epithelial junctions in airway epithelial cells, leading to increased permeability and allowing bacteria to transmigrate across the epithelial barrier. The ADPRT domain of ExoS was at least partly responsible for these events.
35. Sun J., and Barbieri J.T. Pseudomonas aeruginosa ExoT ADP-ribosylates CT10 regulator of kinase (Crk) proteins. J Biol Chem 278 (2003) 32794-32800
36. Pielage J.F., Powell K.R., Kalman D., and Engel J.N. RNAi screen reveals an Abl kinase-dependent host cell pathway involved in Pseudomonas aeruginosa internalization. PLoS Pathog 4 (2008) e1000031
37. Garrity-Ryan L., Shafikhani S., Balachandran P., Nguyen L., Oza J., Jakobsen T., Sargent J., Fang X., Cordwell S., Matthay M.A., et al. The ADP ribosyltransferase domain of Pseudomonas aeruginosa ExoT contributes to its biological activities. Infect Immun 72 (2004) 546-558
38. Shafikhani S.H., Morales C., and Engel J. The Pseudomonas aeruginosa type III secreted toxin ExoT is necessary and sufficient to induce apoptosis in epithelial cells. Cell Microbiol 10 (2008) 994-1007. This paper, along with [28], reveals unexpected roles for ExoT and for Crk in host cell biology. The authors demonstrate that ExoT is necessary and sufficient to induce apoptosis, probably through inactivation of Crk adaptor proteins. Together with its ability to inhibit cytokinesis and cell migration, this study demonstrates why ExoT is a potent inhibitor of wound repair.
39. Balachandran P., Dragone L., Garrity-Ryan L., Lemus A., Weiss A., and Engel J. The ubiquitin ligase Cbl-b limits Pseudomonas aeruginosa exotoxin T-mediated virulence. J Clin Invest 117 (2007) 419-427. Through in vitro and in vivo studies, the authors demonstrate that by binding Crk, ExoT recruits the ubiquitin ligase Cbl-b. ExoT becomes ubiquinated and undergoes proteosomal degradation. Enhanced bacterial persistence and dissemination are observed in a Cbl-b deficient mouse in an ExoT-specific manner. This study represents the first identification of a mammalian gene product that is specifically required for in vivo resistance to disease mediated by a T3SS effector.
40. Viboud G.I., and Bliska J.B. Yersinia outer proteins: role in modulation of host cell signalling responses and pathogenesis. Annu Rev Microbiol 59 (2005) 69-89
41. Miao E.A., Alpuche-Aranda C.M., Dors M., Clark A.E., Bader M.W., Miller S.I., and Aderem A. Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1beta via Ipaf. Nat Immunol 7 (2006) 569-575
42. Franchi L., Stoolman J., Kanneganti T.D., Verma A., Ramphal R., and Nunez G. Critical role for Ipaf in Pseudomonas aeruginosa-induced caspase-1 activation. Eur J Immunol 37 (2007) 3030-3039. The authors show that P. aeruginosa flagellin was essential for caspase-1-dependent activation of IL-1beta and that neither ExoS, ExoT, nor ExoY inhibited this Ipaf-dependent pathway.
43. •], the authors had shown that ExoS inhibits caspase-1-dependent activation of IL-1beta by the P. aeruginosa T3SS.
44. Lee V.T., Smith R.S., Tummler B., and Lory S. Activities of Pseudomonas aeruginosa effectors secreted by the Type III secretion system in vitro and during infection. Infect Immun 73 (2005) 1695-1705
45. Zhuo H., Yang K., Lynch S.V., Dotson R.H., Glidden D.V., Singh G., Webb W.R., Elicker B.M., Garcia O., Brown R., et al. Increased mortality of ventilated patients with endotracheal Pseudomonas aeruginosa without clinical signs of infection. Crit Care Med 36 (2008) 2495-2503. The authors demonstrate that T3SS-proficient strains of P. aeruginosa are associated with increased mortality in ventilated patients that do not meet the clinical criteria for pneumonia. These patients also had higher bacterial burdens than patients colonized with strains whose T3SS was non-functional. The study suggests that colonization with T3SS-proficient strains of P. aeruginosa is associated with increased mortality.
46. Lee V.T., Pukatzki S., Sato H., Kikawada E., Kazimirova A.A., Huang J., Li X., Arm J.P., Frank D.W., and Lory S. Pseudolipasin A is a specific inhibitor for phospholipase A2 activity of Pseudomonas aeruginosa cytotoxin ExoU. Infect Immun 75 (2007) 1089-1098. In a high-throughput cell-based assay to screen compound libraries that protected cells against the cytotoxic effects of ExoU, the authors identified a novel inhibitor of ExoU-specific phospholipase A2 activity.
47. Felise H.B., Nguyen H.V., Pfuetzner R.A., Barry K.C., Jackson S.R., Blanc M.P., Bronstein P.A., Kline T., and Miller S.I. An inhibitor of gram-negative bacterial virulence protein secretion. Cell Host Microbe 4 (2008) 325-336. The investigators used high-throughput screening to identify a novel class of small molecules that inhibit T3SS.
48. Sawa T., Yahr T.L., Ohara M., Kurahashi K., Gropper M.A., Wiener-Kronish J.P., and Frank D.W. Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury. Nat Med 5 (1999) 392-398
49. Imamura Y., Yanagihara K., Fukuda Y., Kaneko Y., Seki M., Izumikawa K., Miyazaki Y., Hirakata Y., Sawa T., Wiener-Kronish J.P., et al. Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model. Eur Respir J 29 (2007) 965-968
50. Corech R., Rao A., Laxova A., Moss J., Rock M.J., Li Z., Kosorok M.R., Splaingard M.L., Farrell P.M., and Barbieri J.T. Early immune response to the components of the type III system of Pseudomonas aeruginosa in children with cystic fibrosis. J Clin Microbiol 43 (2005) 3956-3962